2011
DOI: 10.1016/j.ejphar.2010.10.058
|View full text |Cite
|
Sign up to set email alerts
|

Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

2
15
0

Year Published

2012
2012
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(17 citation statements)
references
References 43 publications
2
15
0
Order By: Relevance
“…These results are reflective of the work of others (Giner et al, 2011;Kimachi et al, 2011;Koch et al, 2012), who observed that aminobisphosphonates, including alendronate and zoledronate, posed a modulatory effect on RANKL activity in osteoblastic cells. Considering that in this model the effect of bisphosphonates on an osteocytic network is being assessed, the results may be significant in further demonstrating the biochemical effect of osteoporotic drugs, most notably so in a model of microinjury in bone.…”
Section: Discussionsupporting
confidence: 70%
“…These results are reflective of the work of others (Giner et al, 2011;Kimachi et al, 2011;Koch et al, 2012), who observed that aminobisphosphonates, including alendronate and zoledronate, posed a modulatory effect on RANKL activity in osteoblastic cells. Considering that in this model the effect of bisphosphonates on an osteocytic network is being assessed, the results may be significant in further demonstrating the biochemical effect of osteoporotic drugs, most notably so in a model of microinjury in bone.…”
Section: Discussionsupporting
confidence: 70%
“…The loss of MMP2 can result in defects in osteoblast growth and decreased BMD at the tissue level . More importantly, the RANKL/OPG system has been widely reported as a major signaling pathway that regulates bone resorption . The increased RANKL/OPG ratio in the vibrated cell group favors osteoclastogenesis and bone resorption.…”
Section: Discussionmentioning
confidence: 99%
“…The OVX model (group III) displayed significant bone loss after 12 weeks as depicted by evident reduction in the bone mineral contents (BMCs) of Ca in the femur as compared with an age-matched sham group. However, OPG functions as a soluble decoy receptor to RANKL and competes with RANK for RANKL binding to inhibit OC recruitment, thereby controlling OB-OC activity balance [37][38][39]. Low estradiol is certainly one possible RANK receptor on hematopoietic OC precursor cells enhances OC recruitment and activation.…”
Section: Discussionmentioning
confidence: 99%